Pharming Group NV Sponsored ADR PHAR 深 滬
等待開盤 06-15 09:30:00 美东时间
12.805
-0.075
-0.58%
華盛通- 最 高12.98
- 今 開12.7005
- 成交量 6849股
- 最 低 12.7005
- 昨 收 12.88
- 總市值 90.44万
- 52周最高 21.34
- 市盈率 靜 334.33
- 換手率 0.01%
- 52周最低 9.5354
- 委 比 69.23%
- 總股本 7.06万
- 歷史最高 21.99
- 量 比 1.12
- 振 幅 2.17%
- 歷史最低 6.10
- 每 手 1
- 風險率 2.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pharming Says FDA Accepts Joenja Application for Younger Children
Pharming Group ((Euronext: PHARM, NASDAQ:PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja®
06-04 16:21
Pharming Group announces results of 2026 Annual General Meeting of Shareholders
Pharming Group shareholders approved all proposals at the 2026 Annual General Meeting, including appointing KPMG as the external auditor for 2026-2028, amending the Board's remuneration policy, and renewing share issuance and repurchase authorizations. Meeting materials are available on the company's website.
05-28 14:40
European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union
Joenja® (leniolisib) has been granted marketing authorization by the European Commission for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency, in adults and pediatric patients aged 12 years and older. This marks the first approval for APDS in the European Union. The first European launch is expected in Germany in Q3 2026, with additional launches pending national reimbursement neg...
05-22 19:30
Pharming Group Balances Short-Term Strain With Pipeline Gains
Pharming Group N.V. (($NL:PHARM)) has held its Q1 earnings call. Read on for th...
05-08 09:23
Pharming Group shares are trading lower after the company reported worse-than-expected Q1 financial results.
Pharming Group shares are trading lower after the company reported worse-than-e...
05-07 20:52
Pharming Affirms FY2026 Sales Guidance of $405.000M-$425.000M vs $421.375M Est
Pharming (NASDAQ:PHAR) affirms FY2026 sales outlook from $405.000 million-$425.000 million to $405.000 million-$425.000 million vs $421.375 million estimate.
05-07 20:42
Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures up, Dow futures gain 0.1% as Snap (NYSE: SNAP) shares fall 10.5%, Fastly (NASDAQ: FSLY) down 21.6%, and other stocks decline in pre-market trading.
05-07 20:04
Pharming Projects FY2026 Total Revenues Of $405M-$425M With 8%-13% Growth Amid Pipeline Investments And Cost Reductions
For 2026, the Company anticipates: Total revenues between US$405 million and US$425 million (8% to 13% growth), with quarterly fluctuations expected.Total operating expenses between US$330 million and US$335 million
05-07 14:02
Pharming Q1 EPS $(0.07) Misses $0.01 Estimate, Sales $72.400M Miss $93.750M Estimate
Pharming (NASDAQ:PHAR) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.01 by 800 percent. This is a 68.18 percent increase over losses of $(0.22) per share from the same
05-07 13:41
Pharming presents interim pediatric leniolisib extension study data in APDS at CIS 2026
Pharming presents interim pediatric leniolisib extension study data in APDS at CIS 2026 Pharming Group flagged new clinical readouts for leniolisib, with interim pediatric APDS outcomes slated for presentation at Clinical Immunology Society (CIS) 2026 in New Orleans during May 6-9. Disclosures will
05-07 13:14
